NYSEAMERICAN:CVM - Cel-Sci Stock Price, Price Target & More

$1.83 -0.07 (-3.68 %)

(As of 04/20/2018 04:00 PM ET)

Previous Close$1.83

Today's Range$1.7801 - $1.88

52-Week Range$1.30 - $4.00

Volume37,782 shs

Average Volume186,330 shs

Market Capitalization$25.49 million

P/E RatioN/A

Dividend YieldN/A

Beta-1.29

About Cel-Sci (NYSEAMERICAN:CVM)

CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

Receive CVM News and Ratings via Email

Sign-up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

SymbolNYSEAMERICAN:CVM

CUSIPN/A

Webwww.cel-sci.com

Phone+1-703-5069460

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / CashN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net Margins-5,432.69%

Return on EquityN/A

Return on Assets-110.07%

Miscellaneous

EmployeesN/A

Outstanding Shares16,500,000

How to Become a New Pot Stock Millionaire

Cel-Sci (NYSEAMERICAN:CVM) Frequently Asked Questions

What is Cel-Sci's stock symbol?

Cel-Sci trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."

How were Cel-Sci's earnings last quarter?

Cel-Sci Co. (NYSEAMERICAN:CVM) announced its quarterly earnings data on Monday, February, 12th. The company reported ($0.53) EPS for the quarter. The firm earned $0.11 million during the quarter. View Cel-Sci's Earnings History.

When is Cel-Sci's next earnings date?

Cel-Sci is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Cel-Sci.

Are investors shorting Cel-Sci?

Cel-Sci saw a drop in short interest in the month of March. As of March 29th, there was short interest totalling 664,027 shares, a drop of 26.0% from the March 15th total of 897,860 shares. Based on an average daily trading volume, of 173,399 shares, the days-to-cover ratio is presently 3.8 days. Currently, 4.2% of the shares of the company are sold short.

Who are some of Cel-Sci's key competitors?

Some companies that are related to Cel-Sci include Abzena (ABZA), Scancell (SCLP), Immutep (IMMP), Catabasis Pharmaceuticals (CATB), TRACON Pharmaceuticals (TCON), Neovasc (NVCN), CytRx (CYTR), VolitionRX (VNRX), Imprimis Pharmaceuticals (IMMY), Arch Therapeutics (ARTH), AzurRx BioPharma (AZRX), Novus Therapeutics (NVUS), Proteon Therapeutics (PRTO), Caladrius Biosciences (CLBS), Pure Bioscience (PURE), Vivus (VVUS), Omnicomm Systems (OMCM) and IntelGenx Technologies (IGXT).

Who are Cel-Sci's key executives?

Cel-Sci's management team includes the folowing people:

Mr. Geert R. Kersten, Chief Exec., Financial & Accounting Officer, Treasurer and Director (Age 59)
Ms. Patricia B. Prichep, Sr. VP of Operations & Corp. Sec. (Age 67)
Dr. Eyal Talor, Chief Scientific Officer (Age 62)
Dr. Daniel H. Zimmerman, Sr. VP of Research - Cellular Immunology (Age 77)
Mr. John Cipriano, Sr. VP of Regulatory Affairs (Age 76)

Has Cel-Sci been receiving favorable news coverage?

Media coverage about CVM stock has trended positive recently, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cel-Sci earned a news impact score of 0.29 on Accern's scale. They also assigned news stories about the company an impact score of 46.59 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Cel-Sci?

Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cel-Sci's stock price today?

One share of CVM stock can currently be purchased for approximately $1.83.

How big of a company is Cel-Sci?

Cel-Sci has a market capitalization of $25.49 million.

How can I contact Cel-Sci?

Cel-Sci's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The company can be reached via phone at +1-703-5069460.

MarketBeat Community Rating for Cel-Sci (CVM)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		59 (Vote Outperform)
Underperform Votes:		65 (Vote Underperform)
Total Votes:		124

MarketBeat's community ratings are surveys of what our community members think about Cel-Sci and other stocks. Vote "Outperform" if you believe CVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Cel-Sci (NYSEAMERICAN:CVM) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

1 Wall Street analysts have issued ratings and price targets for Cel-Sci in the last 12 months. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.00	2.00	2.00	2.00
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	N/A	N/A	N/A	N/A
Price Target Upside:	N/A	N/A	N/A	N/A

Cel-Sci (NYSEAMERICAN:CVM) Consensus Price Target History

Price Target History for Cel-Sci (NYSEAMERICAN:CVM)

Cel-Sci (NYSEAMERICAN:CVM) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Details
10/16/2017	Dawson James	Reiterated Rating	Neutral

(Data available from 4/21/2016 forward)

Cel-Sci (NYSEAMERICAN:CVM) Earnings History and Estimates Chart

Earnings by Quarter for Cel-Sci (NYSEAMERICAN:CVM)

Cel-Sci (NYSEAMERICAN CVM) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/9/2018
2/12/2018	Q1 2018		($0.53)		$0.11 million	View	N/A
12/29/2017	Q4 2017		($0.58)		$0.02 million	View	N/A
8/9/2017	Q3 2017		($0.53)		$0.02 million	View	N/A
5/10/2017	Q2 2017		($0.05)		$0.02 million	View	N/A
2/9/2017	Q116		$0.01		$0.01 million	View	N/A
12/14/2016	Q4 2016		($0.25)		$0.10 million	View	N/A
8/10/2016	Q316		($0.03)		$0.13 million	View	N/A
5/10/2016	Q2		($0.07)		$0.03 million	View	N/A
2/9/2016	Q1 2016		$0.50		$0.02 million	View	N/A
12/11/2015	Q4 2015		($2.50)		($0.07) million	View	N/A
8/7/2015	Q3 2015		($1.50)		$0.39 million	View	N/A
5/8/2015	Q2 2015	($0.12)	($0.17)	$0.10 million	$0.20 million	View	N/A
2/6/2015	Q1 2015	($0.09)	($0.11)	$0.07 million	$0.14 million	View	N/A
12/23/2014	Q4 2014	($2.25)	($2.75)	$0.04 million	$0.07 million	View	N/A
8/8/2014	Q3 2014		($2.75)		$0.02 million	View	N/A
5/13/2014	Q114	($0.11)	($0.24)	$0.02 million	$0.0672 million	View	N/A
2/11/2014	Q413	($0.11)	($0.15)	$510.39 million	$0.11 million	View	N/A
1/2/2014	Q3		($0.27)		$0.02 million	View	N/A
8/9/2013	Q3 2013	($5.00)	($5.00)	$0.10 million	$0.11 million	View	N/A
5/14/2013	Q213		($0.01)		$0.07 million	View	N/A
2/8/2013	Q1 2013		($0.01)			View	N/A
12/14/2012	Q4 2012	($5.00)	($5.00)			View	N/A
8/9/2012	Q3 2012		($3.00)			View	N/A
5/10/2012	Q2 2012		($10.25)			View	N/A
2/9/2012	Q1 2012		($4.50)			View	N/A
12/23/2011	Q4 2011		($3.25)			View	N/A
8/9/2011	Q3 2011		($6.25)			View	N/A
5/16/2011	Q2 2011		($9.25)			View	N/A
2/10/2011	Q1 2011		($7.50)			View	N/A
12/13/2010	Q4 2010		($7.50)			View	N/A
8/16/2010	Q3 2010		($2.50)			View	N/A
5/17/2010	Q2 2010		($7.00)			View	N/A
2/16/2010	Q1 2010		$5.00			View	N/A
1/13/2010	Q4 2009		($58.50)			View	N/A
8/14/2009	Q3 2009		($12.75)			View	N/A
5/15/2009	Q2 2009		($4.00)			View	N/A
8/19/2008	Q3 2008		$5.00			View	N/A
5/16/2008	Q2 2008		($7.75)			View	N/A
2/14/2008	Q1 2008		($5.00)			View	N/A
1/14/2008	Q4 2007		($2.50)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Cel-Sci (NYSEAMERICAN:CVM) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Cel-Sci (NYSEAMERICAN CVM) Insider Trading and Institutional Ownership History

Insider Trading History for Cel-Sci (NYSEAMERICAN:CVM)

Cel-Sci (NYSEAMERICAN CVM) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/16/2018	Peter R Young	Director	Buy	6,500	$1.80	$11,700.00	3,691
1/22/2018	Eyal Talor	Insider	Sell	8,192	$2.06	$16,875.52	117,698
1/16/2018	Eyal Talor	Insider	Sell	1,808	$2.15	$3,887.20	121,156
1/12/2018	Eyal Talor	Insider	Sell	101	$2.15	$217.15	121,156
10/17/2017	Vicente Benjamin Asuncion	Director	Sell	160,000	$0.39	$62,400.00
8/25/2017	Eyal Talor	Insider	Sell	769	$1.91	$1,468.79	118,543
8/16/2017	Eyal Talor	Insider	Sell	14,019	$2.61	$36,589.59	131,312
10/13/2014	Geert R Kersten	CEO	Buy	14,999	$0.77	$11,549.23
12/30/2013	Geert R Kersten	CEO	Buy	300,000	$0.60	$180,000.00
10/9/2013	Geert R Kersten	Insider	Buy	8,400	$0.79	$6,636.00
6/19/2013	Peter R Young	Director	Buy	25,000	$0.24	$6,000.00
6/14/2013	Geert R Kersten	Insider	Buy	145,120	$0.24	$34,828.80
5/20/2013	Geert R Kersten	CEO	Buy	40,000	$0.25	$10,000.00
5/2/2013	Geert R Kersten	CEO	Buy	118,700	$0.27	$32,049.00
3/27/2013	Peter R Young	Director	Buy	25,000	$0.23	$5,750.00
3/26/2013	Geert R Kersten	CEO	Buy	348,125	$0.21	$73,106.25

(Data available from 1/1/2013 forward)

Cel-Sci (NYSEAMERICAN CVM) News Headlines

Source:

Date	Headline
	Peter R. Young Acquires 6,500 Shares of Cel-Sci Co. (CVM) Stock www.americanbankingnews.com - April 17 at 1:23 PM
	Should You Worry About CEL-SCI Corporation’s (NYSEMKT:CVM) CEO Pay? finance.yahoo.com - April 11 at 3:58 PM
	Cel-Sci Co. (CVM) Sees Significant Decrease in Short Interest www.americanbankingnews.com - April 11 at 2:04 AM
	Cel-Sci (CVM) Upgraded to "Sell" at ValuEngine www.americanbankingnews.com - April 10 at 5:02 PM
	CEL-SCI Corporation to Present at The MicroCap Conference finance.yahoo.com - April 9 at 10:22 AM
	Cel-Sci (CVM) Receives "Neutral" Rating from Dawson James www.americanbankingnews.com - April 6 at 4:46 PM
	CEL-SCI Corporation Issues Letter to Shareholders finance.yahoo.com - April 4 at 5:40 PM
	Form 4 CEL SCI CORP For: Mar 30 Filed by: PRICHEP PATRICIA B www.streetinsider.com - April 3 at 10:27 AM
	Form 4 CEL SCI CORP For: Mar 30 Filed by: ZIMMERMAN DANIEL H www.streetinsider.com - April 3 at 10:27 AM
	Multikine Immunotherapy: Cel-Sci Is Weathering The Storm seekingalpha.com - April 2 at 3:59 PM
	CEL-SCI Co. (CVM) Short Interest Down 7.0% in March www.americanbankingnews.com - March 27 at 1:02 AM
	With A -133.58% Earnings Drop, Is CEL-SCI Corporation’s (NYSEMKT:CVM) A Concern? finance.yahoo.com - March 14 at 11:25 AM
	CEL-SCI Co. (CVM) Short Interest Update www.americanbankingnews.com - March 10 at 3:15 AM
	Who Are CEL-SCI Corporation’s (NYSEMKT:CVM) Major Shareholders? finance.yahoo.com - February 28 at 10:04 AM
	Short Interest in CEL-SCI Co. (CVM) Increases By 56.3% www.americanbankingnews.com - February 27 at 6:00 PM
	CEL-SCI (CVM) Releases Earnings Results www.americanbankingnews.com - February 13 at 10:50 AM
	CEL-SCI Corporation Reports First Quarter Fiscal 2018 Financial Results finance.yahoo.com - February 13 at 8:42 AM
	Cel-Sci reports 1Q loss finance.yahoo.com - February 13 at 8:42 AM
	CEL-SCI to Present Tomorrow at 2018 BIO CEO & Investor Conference finance.yahoo.com - February 12 at 5:02 PM
	CEL-SCI Co. (CVM) Sees Large Decrease in Short Interest www.americanbankingnews.com - February 9 at 6:56 PM
	CEL-SCI to Present at 2018 BIO CEO & Investor Conference finance.yahoo.com - February 5 at 4:49 PM
	CEL-SCI Corp (CVM) Announces US Patent Office Allows New Patent For LEAPS Vaccine Platform Technology - StreetInsider.com www.streetinsider.com - January 31 at 8:51 AM
	U.S. Patent Office Allows New CEL-SCI Patent For LEAPS Vaccine Platform Technology finance.yahoo.com - January 30 at 4:55 PM
	Short Interest in CEL-SCI Co. (CVM) Grows By 48.9% www.americanbankingnews.com - January 24 at 6:10 PM
	CEL-SCI Co. (CVM) Insider Sells $16,875.52 in Stock www.americanbankingnews.com - January 22 at 7:04 PM
	Active-Investors: Wired News - Pluristem's PLX Cells Demonstrated Inhibition of Cancer Cell Growth in Peer-Reviewed Article www.finanznachrichten.de - January 17 at 8:27 AM
	Wired News – Pluristem’s PLX Cells Demonstrated Inhibition of Cancer Cell Growth in Peer-Reviewed Article finance.yahoo.com - January 17 at 8:26 AM
	CEL-SCI Awarded Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis - Business Wire (press release) www.businesswire.com - January 8 at 11:51 AM
	CEL-SCI Awarded Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis finance.yahoo.com - January 8 at 9:50 AM
	CEL-SCI Issues Letter to Shareholders - Business Wire (press release) www.businesswire.com - January 4 at 8:47 AM
	CEL-SCI Issues Letter to Shareholders finance.yahoo.com - January 3 at 8:46 AM
	CEL-SCI Reports Fiscal 2017 Financial Results and Clinical & Corporate Developments finance.yahoo.com - December 29 at 5:09 PM
	What Is The Future Prospect For Healthcare And CEL-SCI Corporation (NYSEMKT:CVM)? finance.yahoo.com - December 29 at 10:08 AM
	What Did CEL-SCI Corporation’s (NYSEMKT:CVM) CEO Take Home Last Year? finance.yahoo.com - December 21 at 8:45 AM
	CEL-SCI Corp (CVM) Appoints Robert Watson to Board - StreetInsider.com www.streetinsider.com - December 19 at 5:13 PM
	CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study - Business Wire (press release) www.businesswire.com - December 12 at 10:02 AM
	Short Interest in CEL-SCI Co. (CVM) Drops By 11.8% www.americanbankingnews.com - December 12 at 2:26 AM
	CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study finance.yahoo.com - December 11 at 5:26 PM
	CEL-SCI Reports Recent Data Review By the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head ... - Business Wire (press release) www.businesswire.com - December 9 at 8:44 AM
	CEL-SCI Corp (CVM) Reports Data Review By IDMC for Its Pivotal Phase 3 Head and Neck Cancer Study - StreetInsider.com www.streetinsider.com - December 8 at 9:36 AM
	CEL-SCI (CVM) Scheduled to Post Quarterly Earnings on Tuesday www.americanbankingnews.com - December 5 at 1:44 AM
	CEL-SCI Corporation’s (CVM) EPS Grew 65.7% In A Year. Was It Better Than Long-Term Trend? finance.yahoo.com - November 30 at 8:54 AM
	Short Interest in CEL-SCI Co. (CVM) Declines By 10.2% www.americanbankingnews.com - November 27 at 9:56 PM
	Flaherty Financial Newsletter Spotlights "CEL-SCI Corporation's Global Phase 3 Cancer Immunotherapy Treatment Nearing the Finish Line" in Flaherty Financial Newsletter #60 finance.yahoo.com - November 14 at 6:05 PM
	CEL-SCI Announces Update on Arbitration against Former Clinical Research Organization finance.yahoo.com - November 13 at 12:36 PM

Cel-Sci (NYSEAMERICAN:CVM) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Cel-Sci (NYSEAMERICAN:CVM) Income Statement, Balance Sheet and Cash Flow Statement

Cel-Sci (NYSEAMERICAN CVM) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff